Vertigo Research Today is a free monthly online journal that collates and summarizes the latest research about Vertigo, including details on causes, symptoms, treatment, dizziness.

Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study.

Rask-Andersen H, Friberg U, Johansson M, Stjernschantz J

Department of Otosurgery, University Hospital, Uppsala, Sweden. helge.rask-andersen@akademiska.se

OBJECTIVE: To determine the short-term effects of latanoprost, a selective FP prostanoid receptor agonist, in Meniere's disease. STUDY DESIGN AND METHODS: Latanoprost was administered by intratympanic injection once daily for 3 days. Before the first injection (day 1) and on days 5 and 15, hearing and tinnitus were determined. The patients assessed vertigo on a visual analogue scale on days 1-15. The study was randomized, double-blind, and placebo-controlled. RESULTS: Latanoprost reduced vertigo/dysequilibrium around 30% (P < 0.05), and improved speech discrimination around 15% (P < 0.05). Tinnitus loudness deteriorated after injection of placebo (P < 0.01) but not after latanoprost. Side effects were few. CONCLUSION AND SIGNIFICANCE: Latanoprost alleviated vertigo/dysequilibrium and improved hearing. The results indicate that the drug potentially could be useful for treatment of Meniere's disease.

Published 6 September 2005 in Otolaryngol Head Neck Surg, 133(3): 441-3.
Full-text of this article is available online (may require subscription).

© 2005-2008 Vertigo Research Today. All Rights Reserved.